STOCK TITAN

Actinium CSO reports 213,648 RSUs, 120K options

CSO Kamal Adeela reports initial holdings in ATNM, including time-vested RSUs and long-dated stock options.

(Moderate)
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Actinium Pharmaceuticals, Inc. (ATNM) reported the initial equity holdings of Chief Scientific Officer Kamal Adeela. The filing lists 213,648 shares of Common Stock in the form of restricted stock units and stock options over 120,000 shares of Common Stock.

Of the restricted stock units, 80,000 vest in three equal installments on September 2, 2027, September 2, 2028 and September 2, 2029, and 133,648 vest on September 2, 2029. The stock options have an exercise price of $1.00 per share, vest in fifty equal monthly tranches beginning on October 2, 2026, and expire on September 2, 2036.

Positive

  • None.

Negative

  • None.
Insider Kamal Adeela
Role Chief Scientific Officer
Type Security Shares Price Value
holding Stock Option (Right to Buy) F2 -- -- --
holding Common Stock F1 -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 120,000 contracts (Direct); Common Stock — 213,648 shares (Direct)
Footnotes (2)
  1. F1. Represents restricted stock units ("RSUs"). 80,000 of the RSUs vest as follows: 1/3 on September 2, 2027, 1/3 on September 2, 2028, and 1/3 on September 2, 2029. 133,648 of the RSUs vest on September 2, 2029.
  2. F2. The stock options vest and become exercisable in fifty equal monthly tranches beginning on October 2, 2026.
Restricted stock units 213,648 shares Total restricted stock units reported as Common Stock holdings
RSUs vesting in three installments 80,000 shares Vesting 1/3 on September 2, 2027, 1/3 on September 2, 2028, 1/3 on September 2, 2029
RSUs vesting on a single date 133,648 shares Restricted stock units vesting on September 2, 2029
Stock option underlying shares 120,000 shares Underlying common shares subject to reported stock options
Option exercise price $1.00 per share Exercise price of stock options over 120,000 shares
Option expiration date September 2, 2036 Expiration date of the reported stock options
Option vesting tranches 50 monthly tranches Vesting begins on October 2, 2026 in fifty equal monthly tranches
restricted stock units financial
"Represents restricted stock units ("RSUs"). 80,000 of the RSUs vest as follows"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSUs financial
"Represents restricted stock units ("RSUs"). 80,000 of the RSUs vest as follows"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
stock options financial
"The stock options vest and become exercisable in fifty equal monthly tranches"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
vest financial
"80,000 of the RSUs vest as follows: 1/3 on September 2, 2027"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

What does the ATNM Form 3 disclose about Kamal Adeela's equity holdings?

The Form 3 discloses that Chief Scientific Officer Kamal Adeela holds 213,648 restricted stock units and stock options over 120,000 shares of Actinium Pharmaceuticals, Inc. common stock, subject to specified vesting schedules and an option exercise price of $1.00 per share.

How many ATNM restricted stock units does Kamal Adeela hold and how do they vest?

Kamal Adeela holds 213,648 restricted stock units. 80,000 vest in three equal installments on September 2, 2027, September 2, 2028 and September 2, 2029, and 133,648 vest on September 2, 2029, as disclosed in the filing’s footnote.

What stock options in ATNM does Kamal Adeela report on the Form 3?

The Form 3 reports stock options giving Kamal Adeela the right to acquire 120,000 shares of Actinium Pharmaceuticals, Inc. common stock at an exercise price of $1.00 per share, with an expiration date of September 2, 2036.

What is the vesting schedule for Kamal Adeela’s ATNM stock options?

The filing states that Kamal Adeela’s stock options vest and become exercisable in fifty equal monthly tranches beginning on October 2, 2026. These options relate to 120,000 underlying shares of Actinium Pharmaceuticals, Inc. common stock.

Are there any stock sales or purchases reported in Kamal Adeela’s ATNM Form 3?

No stock sales or purchases are reported. The Form 3 is an initial statement of beneficial ownership and lists holdings in restricted stock units and stock options, without reporting any buy or sell transactions in Actinium Pharmaceuticals, Inc. common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Kamal Adeela

(Last)(First)(Middle)
C/O ACTINIUM PHARMACEUTICALS, INC.
100 PARK AVE., 23RD FLOOR

(Street)
NEW YORK NEW YORK 10017

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
09/03/2026
3. Issuer Name and Ticker or Trading Symbol
Actinium Pharmaceuticals, Inc. [ ATNM ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Scientific Officer
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock213,648(1)D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) (2)09/02/2036Common Stock120,000$1D
Explanation of Responses:
1. Represents restricted stock units ("RSUs"). 80,000 of the RSUs vest as follows: 1/3 on September 2, 2027, 1/3 on September 2, 2028, and 1/3 on September 2, 2029. 133,648 of the RSUs vest on September 2, 2029.
2. The stock options vest and become exercisable in fifty equal monthly tranches beginning on October 2, 2026.
/s/ Adeela Kamal09/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Keep reading